Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$11.36 USD
-0.69 (-5.73%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $11.45 +0.09 (0.79%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COGT 11.36 -0.69(-5.73%)
Will COGT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COGT
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
Other News for COGT
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight
Cogent Biosciences reports Q2 results
Cogent Biosciences Inc Reports Q2 2025 Net Loss of $73.5 Million Amid Increased R&D Expenses
Cogent Biosciences Inc (COGT) Reports Positive Clinical Trial Results and Strong Financial ...
COGT: Bezuclastinib Shows Promising Results in Key Clinical Trial